Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

被引:548
作者
Blonde, Lawrence [1 ]
Khunti, Kamlesh [2 ]
Harris, Stewart B. [3 ]
Meizinger, Casey [4 ]
Skolnik, Neil S. [5 ]
机构
[1] Ochsner Med Ctr, Frank Riddick Diabet Inst, Dept Endocrinol, Ochsner Diabet Clin Res Unit, New Orleans, LA 70121 USA
[2] Univ Leicester, Leicester Gen Hosp, Diabet Res Ctr, Leicester, Leics, England
[3] Western Univ, Western Ctr Publ Hlth & Family Med, Ctr Studies Family Med, Schulich Sch Med & Dent, London, ON, Canada
[4] Abington Jefferson Hlth, Dept Family Med, Abington, PA 19001 USA
[5] Abington Family Med, Jenkintown, PA USA
关键词
Clinical practice; Real-world data; Real-world study; GLARGINE; 300; UNITS/ML; RANDOMIZED CONTROLLED-TRIALS; INSULIN GLUCOSE CONTROL; CARDIOVASCULAR OUTCOMES; DECISION-MAKING; LOWERING DRUGS; TYPE-2; PEOPLE; BASAL; HYPOGLYCEMIA;
D O I
10.1007/s12325-018-0805-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Real-world studies have become increasingly important in providing evidence of treatment effectiveness in clinical practice. While randomized clinical trials (RCTs) are the gold standard for evaluating the safety and efficacy of new therapeutic agents, necessarily strict inclusion and exclusion criteria mean that trial populations are often not representative of the patient populations encountered in clinical practice. Real-world studies may use information from electronic health and claims databases, which provide large datasets from diverse patient populations, and/or may be observational, collecting prospective or retrospective data over a long period of time. They can therefore provide information on the long-term safety, particularly pertaining to rare events, and effectiveness of drugs in large heterogeneous populations, as well as information on utilization patterns and health and economic outcomes. This review focuses on how evidence from real-world studies can be utilized to complement data from RCTs to gain a more complete picture of the advantages and disadvantages of medications as they are used in practice.Funding: Sanofi US, Inc.
引用
收藏
页码:1763 / 1774
页数:12
相关论文
共 60 条
[1]
ABPI, 2017, VIS REAL WORLD DAT O
[2]
[Anonymous], AM DIAB ASS ADA 77 S
[3]
Barnish MS, 2017, PRAGMAT OBS RES, V8, P49, DOI 10.2147/POR.S137701
[4]
REAL WORLD STUDIES, CHALLENGES, NEEDS AND TRENDS FROM THE INDUSTRY [J].
Batrouni, M. ;
Comet, D. ;
Meunier, J. P. .
VALUE IN HEALTH, 2014, 17 (07) :A587-A588
[5]
A comparison of observational studies and randomized, controlled trials. [J].
Benson, K ;
Hartz, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1878-1886
[6]
Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATETM study [J].
Blonde, L. ;
Merilainen, M. ;
Karwe, V. ;
Raskin, P. .
DIABETES OBESITY & METABOLISM, 2009, 11 (06) :623-631
[7]
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3) [J].
Bolli, G. B. ;
Riddle, M. C. ;
Bergenstal, R. M. ;
Ziemen, M. ;
Sestakauskas, K. ;
Goyeau, H. ;
Home, P. D. .
DIABETES OBESITY & METABOLISM, 2015, 17 (04) :386-394
[8]
Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes [J].
Carls, Ginger S. ;
Tuttle, Edward ;
Tan, Ruo-Ding ;
Huynh, Johnny ;
Yee, John ;
Edelman, Steven V. ;
Polonsky, William H. .
DIABETES CARE, 2017, 40 (11) :1469-1478
[9]
Cattell J, 2011, CAN PHARMACOS TAKE A
[10]
Machine Learning and Prediction in Medicine - Beyond the Peak of Inflated Expectations [J].
Chen, Jonathan H. ;
Asch, Steven M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (26) :2507-2509